explore -WSS

explore

author：hotspot 2025-08-25 16:35:03 - browse：594

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： FDA approves first new drug developed for postpartum depression

entertainment

WSS

There’s no way to know how good AI health technologies are

Researchers CRISPR chickens in bid to protect them from bird flu

Biogen nominates mother of director’s child to replace him on board

Nick Jonas talks about managing diabetes along with his career

Female surgeons have lower rates of long

A revolution in caring for preterm infants

hotspot

explore

leisure time

Apple is now the first public company to be valued at $3 trillion

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Activists slam private health insurers over coverage restrictions

Biden administration plans revamp of organ transplant system

Psychedelics group wrestles with new pharma identity

STAT Readout Newsletter: Today in biotech, life science news

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Peter Hotez and the public health issue of online harassment

Eli Lilly’s Mounjaro succeeds in second weight

focus

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Female surgeons have lower rates of long

Senate panel passes drug pricing bills, but drops one PBM reform

Millions may soon lose Medicaid when they don't have to

What the Wegovy shortage looks like for doctors — and for patients

Cancer cells are shown to suck energy source from immune cells

explore

focus

entertainment

hotspot